Grünenthals

Grünenthal is a global pharmaceutical company headquartered in Aachen, Germany. Founded in 1946 by Hermann Josef Breuer and his wife, the company initially focused on producing antibiotics. Over the decades, Grünenthal has expanded its research and development efforts to encompass a range of therapeutic areas, including pain management, orthopedics, and women's health.

The company operates internationally, with subsidiaries and research facilities in numerous countries across Europe, North and South America, and Asia. Grünenthal is known for its commitment to innovation, investing a significant portion of its revenue back into research and development. A key area of focus has been the development of novel analgesics.

Grünenthal's history is also marked by its involvement with the drug thalidomide. Initially marketed as a sedative and treatment for morning sickness in the late 1950s and early 1960s, thalidomide was later found to cause severe birth defects. This tragic event led to significant changes in drug regulation worldwide. Grünenthal has since worked to address the legacy of thalidomide through various initiatives. The company continues its work in developing new medicines, aiming to improve patient outcomes in its chosen therapeutic areas.